UNITED STATES
               SECURITIES AND EXCHANGE COMMISSION

                     WASHINGTON, D.C. 20549

                           FORM 10-QSB

[X]      Quarterly report pursuant to Section 13 or 15 (d) of the
                  Securities Exchange Act of 1934

          For the quarterly period ended  March 31,2006
                                         ---------------

                Commission File Number: 000-25947

                     Biochem Solutions Inc.
----------------------------------------------------------------------
         (Name of Small Business issuer in its Charter)

      Florida                                     65-0386286
----------------------------------------------------------------------
(State or Other Jurisdiction of                    (IRS Employer
 Incorporation or Organization)                 Identification No.)


   Bay & Deveax Streets Nassau, Bahamas          PO Box CR-5464
----------------------------------------------------------------------
(Address of Principal Executive Offices)             (PO Box)


                         (242) 328-1110
----------------------------------------------------------------------
                   (Issuer's Telephone Number)

 Securities registered under Section 12(b) of the Exchange Act:

                              NONE

 Securities registered under Section 12(g) of the Exchange Act:

                   Common Stock, no par value


Check  whether the issuer: (1) filed all reports required  to  be
filed by Section 13 or 15(d) of the Exchange Act during the  past
12  months  (or  for such shorter period that the registrant  was
required to file such reports), and (2) has been subject to  such
filing requirements for the past 90 days.  [ ] YES    [X] NO





Check  if there is no disclosure of delinquent filers in response
to  Item 405 of Regulation S-B is contained in this form, and  no
disclosure  will  be  contained,  to  the  best  of  registrant's
knowledge,   in   definitive  proxy  or  information   statements
incorporated by reference or any amendment to this Form 10-QSB. [ ]

The  issuer is a developmental stage company, and as such has yet
to generate any substantial revenues.

The  aggregate  market value of the voting  stock  held  by  non-
affiliates  of the registrant was not determinable due to lack of
trading.

As  of  November 15, 2006 the issuer had approximately 10,029,000
shares of common stock outstanding.

Documents incorporated by reference: NONE

Transition Small Business Disclosure Format (check one):

               YES [ ]             NO [X]

















                     Biochem Solutions, Inc.

                        Form 10-QSB Index


                                                                      Page

Part I:   Financial Information                                        1

   Item 1.   Financial Statements                                      1

             Condensed Consolidated Balance Sheet - March 31, 2006     1

             Condensed Consolidated Statements of Operations -
             Three months ended March 31, 2006 and 2005                2

             Condensed Consolidated Statements of Cash Flows -
             Three months ended March 31, 2006 and 2005               3-4

             Notes to Financial Statements                            5-11

   Item 2.   Management's Discussion and Analysis or Plan of
             Operation                                                12

Part II:   Other Information

   Item 1.   Legal Proceedings                                        14

   Item 2.   Change in Securities                                     15

   Item 3.   Defaults Upon Senior Securities                          15

   Item 4.   Submission of Matters to a Vote of Security Holders      15

   Item 5.   Subsequent Events                                       15-16

   Item 6.   Exhibits and Reports on Form 8-K                         17

SIGNATURES                                                            17






                 PART I. - FINANCIAL INFORMATION

Item 1. Financial Statements

                     Biochem Solutions, Inc.
                         And Subsidiary
                  (A Development Stage Company)
              Condensed Consolidated Balance Sheet
                           (Unaudited)
                         March 31, 2006

                             Assets
                             ------

        Current assets:
           Cash                                      $     1,969
                                                     -----------

                Total current assets                       1,969

                Property and equipment, net                2,283
                                                     -----------

                Total assets                         $     4,252
                                                     ===========

          Liabilities and Stockholders' Deficiency
          ----------------------------------------

        Current liabilities:
           Accounts payable                          $   191,101
           Accrued expenses                              912,207
           Due to related parties                        269,554
           Notes Payable - related party                 226,466
           Notes payable                                 173,415
                                                     -----------

                Total current liabilities              1,772,743

Stockholders' deficiency:
           Series 2001 convertible preferred stock        42,470
           Series 2001A convertible preferred stock            -
           Series 2001B convertible preferred stock            -
           Class B preferred stock                             -
           Common stock                                5,073,783
           Deferred Compensation                        (333,333)
           Accumulated deficit                        (6,551,412)
                                                     -----------

                Total stockholders' deficiency        (1,768,492)
                                                     -----------
                Total liabilities and stockholders'
                deficiency                           $     4,252
                                                     ===========

See accompanying notes to the condensed consolidated financial statements.


                             1



                     Biochem Solutions, Inc.
                         And Subsidiary
                  (A Development Stage Company)

         Condensed Consolidated Statements of Operations
                           (Unaudited)




                                                                                 Cumulative for
                                                     Three          Three        the period from
                                                     Months         Months       March 23,1999
                                                     Ended          Ended        (inception) to
                                                 March 31, 2006  March 31, 2005  March 31, 2006
                                                 --------------  --------------  --------------
                                                                        
Gross revenues                                     $         -     $         -     $    45,744
Cost of sales                                                -               -             264
                                                 --------------  --------------  --------------
    Net revenue                                              -               -          45,480

Operating Expenses                                     121,950         191,199       5,766,341

Other income(expenses):
    Other income                                             0           1,390         219,657
    Interest expense                                   (10,500)           (454)       (510,181)
    Impairment of Assets                                     0               0        (315,027)
    Provision for loss on non-cancellable
         Lease                                               0               0        (225,000)
                                                 --------------  --------------  --------------

              Total other income(expense)               10,500             936        (830,551)
                                                 --------------  --------------  --------------

              Net Loss                             $  (132,450)    $  (190,263)    $(6,551,412)
                                                 ==============  ==============  ==============
Loss per common share:
    Basic and Diluted                              $    ( 0.00)    $     (0.00)
                                                 ==============  ==============
Weighted average common shares
outstanding:
    Basic and Diluted                              290,957,792      53,315,043
                                                 ==============  ==============


See accompanying notes to the condensed consolidated financial statements.


                             2




                     Biochem Solutions, Inc.
                         And Subsidiary
                  (A Development Stage Company)

         Condensed Consolidated Statements of Cash Flows
                           (Unaudited)




                                                                                 Cumulative for
                                                    Three            Three       the period from
                                                    Months           Months      March 23, 1999
                                                    Ended            Ended       (inception) to
                                                 March 31, 2006  March 31, 2005  March 31, 2006
                                                 --------------  --------------  --------------
                                                                        
Cash flows from operating activities
    Net Loss                                      $   (132,450)   $   (190,263)   $ (6,551,890)
    Adjustments to reconcile net loss to net cash
      used in operating activities
         Forgiveness of related party note payable           -               -         (59,088)
         Depreciation and amortization                     357             268         296,665
         Loss on impairment of assets                        -               -         315,027
         Provision for loss on non-cancelable leases         -               -         225,000
         Bad Debt Expense                                    -               -          42,000
         Intrinsic Value of Stock Options                    -               -         500,000
         Common stock issued for services                    -               -       2,522,072
         Amortization of Deferred Compensation          50,000          50,000         266,667
              Increase(decrease) in cash caused by
                changes in:
                   Other current assets                      -             171               -
                   Accounts payable                      4,523          (1,823)        191,101
                   Accrued expenses                     70,500         138,000         914,763
                   Due from related parties                  -               -         528,642
                                                 --------------  --------------  --------------

         Net cash used in operating activities          (7,071)         (3,647)       (875,708)

Cash flows from investing activities:
    Acquisition of property and equipment                    -          (1,700)       (279,199)

Cash flows from financing activities
    Repayment of note payable to related party               -               -        (200,000)
    Proceeds from issuance of preferred stock                -               -          49,000
    Proceeds from issuance of capital stock                  -               -       1,056,348
    Due to related parties                                   -               -        (399,353)
    Issuance of Note Receivable                                                        (42,000)
    Payment for Preferred Stock                                                        (32,000)
    Repayment/proceeds of notes payable                  9,000               -         724,881
                                                 --------------  --------------  --------------

         Net cash from provided by financing activities  9,000               -       1,156,876
                                                 --------------  --------------  --------------

              Net increase(decrease) in cash             1,929    $     (5,347)   $      1,969

Cash at beginning of period                                 40           6,329               0
                                                 --------------  --------------  --------------

Cash at end of period                             $      1,969    $        982    $      1,969
                                                 ==============  ==============  ==============


See accompanying notes to the condensed consolidated financial statements.


                             3





                     Biochem Solutions, Inc.
                         And Subsidiary
                  (A Development Stage Company)

         Condensed Consolidated Statements of Cash Flows
                           (Unaudited)





                                                                                      Cumulative for
                                                         Three            Three       the period from
                                                         Months           Months      March 23, 1999
                                                         Ended            Ended       (inception) to
                                                      March 31, 2006  March 31, 2005  March 31, 2006
                                                      --------------  --------------  --------------
                                                                              


Supplemental disclosure of cash flow information:
    Cash paid for interest                             $          -    $          -    $     33,495
                                                      ==============  ==============  ==============
Non-cash activity:
    Purchase of intangible assets from related party   $          -    $          -    $    399,353
                                                      ==============  ==============  ==============
         Reduction of capital lease obligation upon
         abandonment of assets                         $          -    $          -    $     65,006
                                                      ==============  ==============  ==============
    Satisfaction of Notes Payable and accrued interest
    by Third Party                                     $          -    $          -    $    487,500
                                                      ==============  ==============  ==============


See accompanying notes to the condensed consolidated financial statements.


                             4




                     Biochem Solutions, Inc.
                         And Subsidiary
                  (A Development Stage Company)

      Notes to Condensed Consolidated Financial Statements
                           (Unaudited)

 (1)    Statement of Information Furnished

      The    accompanying   unaudited   condensed    consolidated
      financial  statements  as of March 31,  2006  and  for  the
      cumulative period from March 23, 1999 (Inception) to  March
      31,  2006  have been prepared in accordance with accounting
      principles  generally  accepted in  the  United  States  of
      America  for  interim  financial information  and  pursuant
      with  the  rules  and  regulations of  the  Securities  and
      Exchange  Commission  for  Form 10-QSB.   Accordingly,  the
      condensed consolidated financial statements do not  include
      all  the  information and notes to the financial statements
      required  by  accounting principles generally  accepted  in
      the   United  States  of  America  for  complete  financial
      statements.    In   the   opinion   of   management,    the
      accompanying  unaudited  condensed  consolidated  financial
      statements  contain  all adjustments  (consisting  of  only
      normal  recurring adjustments) considered necessary  for  a
      fair   presentation   of  Biochem   Solutions,   Inc.   and
      Subsidiary's  financial  position, results  of  operations,
      and  cash  flows for the periods presented.  These  results
      have  been determined on the basis of accounting principles
      generally  accepted  in the United States  of  America  and
      applied consistently with those used in the preparation  of
      the Company's financial statements.

      The  results  of operations for the interim  periods  ended
      March  31, 2006 and 2005 are not necessarily indicative  of
      the  results  to  be  expected for the  full  year.   These
      interim  financial statements should be read in conjunction
      with  the  December  31,  2005  financial  statements   and
      related  notes included in the Company's Annual  Report  on
      Form 10-KSB for the year ended December 31, 2005.

   Going Concern

      The    accompanying   condensed   consolidated    financial
      statements  have  been prepared on a going  concern  basis,
      which  contemplates  the  realization  of  assets  and  the
      satisfaction  of  liabilities  in  the  normal  course   of
      business.  Due  to  its  past financial  difficulties,  the
      Company  has  accumulated  debt,  including  judgments  and
      accrued interest, of approximately $ 1,772,000 relating  to
      its  current  and  former lines of business  and  maintains
      these   on   its  balance  sheet  as  current  liabilities.
      Interest  on  these  balances is  accruing  at  a  rate  of
      approximately  $10,000 per quarter as of  March  31,  2006.
      The  Company is continuing in its efforts to resolve  these
      obligations  and  others  through  settlements.    However,
      there  is  no assurance that the Company will  be  able  to
      settle  in  terms agreeable to the Company and if  it  does
      not  do  so, this will raise substantial doubt  as  to  its
      ability  to  continue as a going concern. As shown  in  the
      condensed  consolidated financial statements,  the  Company
      has   incurred   cumulative  losses  of   approximately   $
      6,600,000 during its development stage.

      The  Company's continuation as a going concern is uncertain
      and   dependent   upon  obtaining  additional   source   of
      financing  and  achieving future profitable operation,  the
      outcome of which cannot be predicted at this time.

      The  condensed  consolidated financial  statements  do  not
      include  any  adjustments to reflect  the  possible  future
      effects on the recoverability and classification of  assets
      or  the amounts and classification of liabilities that  may
      result  from  the  possible inability  of  the  Company  to
      continue as a going concern.


(2)  Summary of Significant Accounting Policies


   The  accounting policies of the Company are in accordance with
   U.S.  GAAP  and their basis of application is consistent  with
   that of the previous year.


                             5



   Recent Accounting Pronouncements

   In  December  2004,  the Financial Accounting  Standard  Board
   ("FASB")  issued  Statement of Accounting  Standards  ("SFAS")
   No.  123  (revised  2004), "Share-Based  Payment"  ("SFAS  No.
   123R").  SFAS  No. 123R requires the Company  to  measure  the
   cost  of  employee services received in exchange for an  award
   of  equity instruments based on the grant-date fair  value  of
   the award. The cost of the employee services is recognized  as
   compensation  cost  over the period that an employee  provides
   service  in  exchange for the award. SFAS  No.  123R  will  be
   effective  January 1, 2006 for the Company and may be  adopted
   using   a   modified   prospective  method   or   a   modified
   retrospective  method. The Company has not  yet  completed  an
   analysis  to  quantify the exact impact the new standard  will
   have on its future financial performance.  Depending upon  the
   extent   to   which   the   Company   implements   share-based
   compensation  plans. Adoption of this statement could  have  a
   material   impact   on   the  Company's  future   consolidated
   financial statements.

   In  December 2004, the FASB issued SFAS No. 153, "Exchanges of
   Non-Monetary   Assets  -  an  amendment  of   the   Accounting
   Principles Board (APB) Opinion No. 29" (Statement 153).   This
   statement  amends  Opinion 29 to eliminate the  exception  for
   non-monetary  exchanges  of  similar  productive  assets   and
   replaces  it  with  a  general  exception  for  exchanges   of
   non-monetary assets that do not have commercial substance.   A
   non-monetary exchange has commercial substance if  the  future
   cash  flows of the entity are expected to change significantly
   as  a  result of the exchange.  The adoption of this  standard
   is  not  expected to have a material impact on  the  Company's
   results of operations or financial position.

   In  March  2005,  the FASB issued FASB Staff Position  ("FSP")
   No.   46(R)-5,   "Implicit  Variable  Interests   under   FASB
   Interpretation   No.  ("FIN")  46  (revised  December   2003),
   Consolidation  of  Variable  Interest  Entities"   ("FSP   FIN
   46R-5").  FSP  FIN  46R-5 provides guidance  for  a  reporting
   enterprise  on whether it holds an implicit variable  interest
   in  Variable Interest Entities ("VIEs") or potential VIEs when
   specific conditions exist. This FSP is effective in the  first
   period  beginning after March 3, 2005 in accordance  with  the
   transition    provisions   of   FIN   46    (Revised    2003),
   "Consolidation   of   Variable   Interest   Entities   -    an
   Interpretation of Accounting Research Bulletin No.  51"  ("FIN
   46R").  The adoption of this standard is not expected to  have
   a  material impact on the Company's results of operations  and
   financial position.


   In   March  2005,  the  FASB  issued  Interpretation  No.  47,
   "Accounting  for  Conditional  Asset  Retirement  Obligations"
   ("FIN   47"),  which  will  result  in  (a)  more   consistent
   recognition  of  liabilities  relating  to  asset   retirement
   obligations, (b) more information about expected  future  cash
   outflows  associated  with  those obligations,  and  (c)  more
   information  about  investments in long-lived  assets  because
   additional asset retirement costs will be recognized  as  part
   of  the carrying amounts of the assets. FIN 47 clarifies  that
   the term "conditional asset retirement obligation" as used  in
   SFAS  143,  "Accounting  for  Asset  Retirement  Obligations,"
   refers  to  a legal obligation to perform an asset  retirement
   activity  in which the timing and/or method of settlement  are
   conditional  on a future event that may or may not  be  within
   the  control  of  the entity. The obligation  to  perform  the
   asset   retirement  activity  is  unconditional  even   though
   uncertainty exists about


                             6



                     Biochem Solutions, Inc.
                         And Subsidiary
                  (A Development Stage Company)
      Notes to Condensed Consolidated Financial Statements
                           (Unaudited)

(2) Summary of Significant Accounting Policies (cont'd)

   the  timing and/or method of settlement. Uncertainty about the
   timing  and/or  method of settlement of  a  conditional  asset
   retirement  obligation should be factored into the measurement
   of  the  liability when sufficient information exists. FIN  47
   also   clarifies   when  an  entity  would   have   sufficient
   information to reasonably estimate the fair value of an  asset
   retirement obligation. FIN 47 is effective no later  than  the
   end   of   fiscal  years  ending  after  December  15,   2005.
   Retrospective application of interim financial information  is
   permitted  but  is  not  required.  Early  adoption  of   this
   interpretation  is encouraged. The adoption of  this  standard
   is  not  expected to have a material impact on  the  Company's
   results of operations and financial position.

   In  May  2005,  the  FASB  issued SFAS  No.  154,  "Accounting
   Changes  and  Error Corrections" ("SFAS 154"), which  replaces
   Accounting   Principles   Board  ("APB")   Opinion   No.   20,
   "Accounting  Changes",  and SFAS No. 3, "Reporting  Accounting
   Changes in Interim Financial Statements - An Amendment of  APB
   Opinion  No.  28".  SFAS  No. 154  provides  guidance  on  the
   accounting   for  and  reporting  of  changes  in   accounting
   principles  and  error  corrections.  SFAS  No.  154  requires
   retrospective   application   to   prior   period    financial
   statements  of  voluntary changes in accounting principle  and
   changes   required  by  new  accounting  standards  when   the
   standard  does  not  include specific  transition  provisions,
   unless  it  is  impracticable to do  so.  SFAS  No.  154  also
   requires   certain   disclosures  for  restatements   due   to
   correction  of  an  error.  SFAS  No.  154  is  effective  for
   accounting  changes and corrections of errors made  in  fiscal
   years  beginning after December 15, 2005, and is  required  to
   be  adopted  by the Company as of January 1, 2006. The  impact
   that  the  adoption of SFAS No. 154 will have on the Company's
   results  of operations and financial condition will depend  on
   the  nature  of  future  accounting  changes  adopted  by  the
   Company  and  the nature of transitional guidance provided  in
   future   accounting  pronouncements.  In  January  2003,   the
   Financial  Accounting  Standards Board  ("SFAS")  issued  SFAS
   Interpretation  No.  46 "Consolidation  of  Variable  Interest
   Entities",  an interpretation of ARAB No. 51 ("FIN  46").  The
   SFAS  issued a revised FIN 46 in December 2003 which  modifies
   and    clarifies    various   aspects    of    the    original
   interpretations.  A  Variable  Interest  Entity   ("VIE")   is
   created  when  (I)  the  equity  investment  at  risk  is  not
   sufficient  to  permit  the entity to finance  its  activities
   without  additional subordinated financial support from  other
   parties  or  (ii)  equity holders either (a)  lack  direct  or
   indirect ability to make decisions about the entity,  (B)  are
   not  obligated to absorb expected losses of the entity or  (C)
   do  not have the right to receive expected residual returns of
   the  entity if they occur. If an entity is deemed to be a VIE,
   pursuant  to FIN 46, an enterprise that absorbs a majority  of
   the  expected  losses  of  the VIE is considered  the  primary
   beneficiary  and  must consolidate the VIE. For  VIEs  created
   before  January 31, 2003, FIN 46 was deferred to  the  end  of
   the  first  or annual period ending after March 15, 2004.  The
   adoption  of FIN 46 is not expected to have a material  impact
   on  the  financial  position or results of operations  of  the
   Company.


(3)   Acquisition of Grupo Industrial N.K.S., S.A., de CV

   As  of March 15, 2005, the Company has completed a transaction
   resulting  in  the  acquisition  of  75%  of  all  issued  and
   outstanding  shares  of NKS. The Company and  stockholders  of
   NKS have mutually agreed that the Company will acquire 75%  of
   all  the  shares  of  NKS in exchange for 250,000,000  of  the
   Company's   common   restricted   shares.   NKS,   a   Mexican
   corporation,  is the owner of a steel mill foundry  and  other
   assets in Lazaro Cardenas, Mexico. The Company has chosen  not
   to  show  any  asset  value for NKS on its Balance  Sheet.  In
   addition,  the  Company  issued 30 million  shares  of  common
   stock  to  an unrelated party as a finder's fee. No value  has
   been attributed to the finder fee.

   The  Company  does not consolidate the financial  position  or
   the statement of operations of its NKS subsidiary.

   On  June  16, 2006, the Company announced that by  Consent  to
   Act in Lieu of a meeting of the shareholders, the majority  of
   the  shareholders of record voted and approved to  unwind  the
   share  exchange  with Grupo Industrial  NKS  SA  de  CV.   The
   250,000,000  shares  issued  to  NKS  shareholders   will   be
   voluntarily  returned  in exchange for  the  75%  of  the  NKS
   shares  held  by  NorMexSteel and the 250,000,000  NorMexSteel
   shares  will  be  cancelled  and  returned  to  treasury.   In
   conjunction with this the shareholders approved to remove  and
   replace  the  existing board of directors; to file  amendments
   to  the  articles of Incorporation of the company  that  would
   effect  a name change to BioChem Solutions Inc. and a  reverse
   stock  split  of the Company's common stock of 1  for  10,000.
   Under  the  guideline  of  the  regulatory  and  company   act
   requirements the majority of shareholders agreed to  the  need
   and  ratio of the reverse stock split and the majority  agreed
   that  the  restructuring  is  in  the  best  interest  of  the
   company.  The  net  effect  of the reverse  stock  split  will
   reduce  the Company's outstanding shares of common stock  post
   split  to 29,066 shares (no fractional shares will be issued).
   The   stock   split  is  effective  as  of  June   30,   2006.
   Shareholders  of  record  will be notified  by  the  Company's
   transfer  agent  and may exchange their old shares  of  common
   stock for new shares of common stock post reverse.


                             7



   On  June  16,  2006, the Company entered into  a  contract  to
   acquire  an  Exclusive Rights and a Master  License  providing
   all  the  rights  in a patented biochemical,  Trioxolane,  and
   other  patents held by the CKD Foundation, the CKD  Foundation
   will appoint five new directors to the board of directors.

   BioChem  Solutions  Inc.  under the Master  License  from  the
   patent holder, the CKD Foundation, will provide funding  on  a
   best  efforts basis for the further development of the patents
   and  applications and related products. BioChem Solutions Inc.
   expects  to  schedule  the  third stage  Clinical  trials  for
   treatment HIV / AIDS.

(4)Capital Stock

   (a) Common Stock
         Authorized
              1,000,000,000 shares                 March 31, 2006
         Issued and outstanding                    --------------
              290,974,585 shares of common stock    $ 5,073,783
                                                   --------------

   During  2004 , the Company entered into an agreement with  the
   CFO  whereby 200,000 common shares were granted for consulting
   services  at  the  inception  of the  agreement.  The  CFO  is
   entitled to a further 100,000 common shares at the end of  the
   second  year  of  the  term of this agreement  and  a  further
   100,000  common  shares at the end of the third  year  of  the
   term  of this agreement. For the three months ended March  31,
   2006,  $50,000  of  which  has been  charged  as  compensation
   expense  included  in Operating Expenses in  the  accompanying
   condensed consolidated statements of operations.

   On  September  29, 2005 the Company's Board approved  a  1:500
   forward split after completing a 500:1 reverse stock split  on
   September  9,  2005  as  approved  by  the  majority  of   the
   shareholders.


   (b) Preferred Stock
       Authorized
            150,000,000                                  September 30, 2005
       Issued and outstanding                            ------------------
           Series 2001 - 22,100 shares of preferred stock      $ 42,470

           Series 2001A-27,488,000 shares of preferred stock        -

           Series 2001B- 30,000,000 shares of preferred stock       -
                                                               --------

           Total 57,510,100 shares of preferred stock          $ 42,470
                                                               --------

(5)  Related Party Transactions

   The  president, current and former principal stockholders, and
   certain employees from time to time made advances or loans  to
   the  Company.   The  advances and loans  have  been  made  for
   financing  and working capital purposes.  At March  31,  2006,
   the  total  of  such  advances and  loans,  including  accrued
   interest, was $269,554.

   The  Company entered into an unsecured funding agreement  with
   Tropical  Ventures/Cazador Enterprises, a shareholder  of  the
   Company,  whereby Tropical will lend the Company  funds  under
   the  following terms;  interest on outstanding amounts of  10%
   per  annum  payable to Cazador Enterprises, a 10% funding  fee
   paid  to  Tropical  Ventures on any  drawdown,  and  no  fixed
   repayment  terms.   As  of March 31,  2006,  the  Company  had
   borrowed  $155,000 less fees of $20,000 provided through  this
   agreement.

                             8




(6)  Accrued Liabilities

   Accrued expenses at March 31, 2006 consisted of the following:


                                             2006
                                             ----

        Accrued lease obligations    $      395,996
        Accrued interest                    165,303
        Accrued Professional Fees           350,909
                                            -------

                                     $      912,208
                                     ==============

(7)   Notes Payable

   The notes payable bear interest at rates that range between 9
   and 12 percent per annum and are due on demand.















                             9






                     Biochem Solutions, Inc.
                         And Subsidiary
                  (A Development Stage Company)
      Notes to Condensed Consolidated Financial Statements
                           (Unaudited)

(8)  Notes Payable - Related Party

   The  related party  notes payable bears an interest rate of 10
   percent per annum and has no fixed terms of repayment.

(9)  Stock Options

   During  2004,  the  Company established a  stock  option  plan
   under which options to purchase shares of common stock may  be
   granted    to   employees,   directors,   officers,    agents,
   consultants and independent contractors.

   During  November  2004,  the Company granted  1,000,000  stock
   options  to  the  Company's  Chief  Financial  Officer.    The
   options  have  an  exercise price of $1.00, vest  immediately,
   and  have  a  term of three years.  At the grant  date,  these
   options  had  an  intrinsic value of $500,000.  These  options
   remain  outstanding at March 31, 2006, are fully  exercisable,
   and have a remaining term of 20 months.


(10)   Income Taxes

   The  Company accounts for income taxes in accordance with SFAS
   No.   109,  "Accounting  for  Income  Taxes".   SFAS  No.  109
   prescribes  the  use of the liability method whereby  deferred
   tax  asset and liability account balances are determined based
   on  differences between financial reporting and tax  bases  of
   assets and liabilities and are measured using the enacted  tax
   rates. The effects of future changes in tax laws or rates  are
   not anticipated.

   Under  SFAS  No.  109  income taxes  are  recognized  for  the
   following: a) amount of tax payable for the current year,  and
   b)   deferred  tax  liabilities  and  assets  for  future  tax
   consequences  of events that have been recognized  differently
   in the financial statements than for tax purposes.

   For  three month period ended March 31, 2006, the Company  had
   approximately  $6,500,000 net operating  loss  carry  forwards
   for  income  tax reporting purposes, which can be utilized  to
   decrease the current year's income taxes.  No tax benefit  was
   reported  in  the current period because the Company  believed
   that  there  was  a  50% or greater chance  the  carryforwards
   would  expire unused.  Accordingly, the potential  benefit  of
   the loss carryforwards were offset by a valuation allowance.

(11)  Commitments and Contingencies

   Several  creditors have taken legal action against the Company
   due  to  defaulted debt and lease obligations.  The  judgments
   total  approximately $378,000.  These amounts are included  in
   accrued liabilities as at March 31, 2006.


                             10



                     Biochem Solutions, Inc.
                         And Subsidiary
                  (A Development Stage Company)
      Notes to Condensed Consolidated Financial Statements
                           (Unaudited)

(12) Subsequent Transactions

On June 16, 2006, the Company announced that by Consent to Act in
Lieu  of  a  meeting  of the shareholders, the  majority  of  the
shareholders  of  record voted and approved to unwind  the  share
exchange  with  Grupo Industrial NKS SA de CV.   The  250,000,000
shares issued to NKS shareholders will be voluntarily returned in
exchange  for  the 75% of the NKS shares held by NorMexSteel  and
the 250,000,000 NorMexSteel shares will be cancelled and returned
to  treasury. In conjunction with this the shareholders  approved
to  remove and replace the existing board of directors;  to  file
amendments  to the articles of Incorporation of the company  that
would  effect  a  name  change to BioChem Solutions  Inc.  and  a
reverse  stock  split  of the Company's common  stock  of  1  for
10,000.  Under  the guideline of the regulatory and  company  act
requirements the majority of shareholders agreed to the need  and
ratio of the reverse stock split and the majority agreed that the
restructuring  is  in the best interest of the company.  The  net
effect  of  the  reverse stock split will  reduce  the  Company's
outstanding  shares of common stock post split to  29,066  shares
(no  fractional  shares  will be issued).   The  stock  split  is
effective  as of June 30, 2006.  Shareholders of record  will  be
notified  by the Company's transfer agent and may exchange  their
old  shares  of common stock for new shares of common stock  post
reverse.

On  June 16, 2006, the Company entered into a contract to acquire
an Exclusive Rights and a Master License providing all the rights
in  a patented BioChemical, Trioxolane, and other patents held by
the  CKD  Foundation, the CKD Foundation will  appoint  five  new
directors to the board of directors.

BioChem  Solutions Inc. under the Master License from the  patent
holder,  the  CKD  Foundation, will provide  funding  on  a  best
efforts  basis  for the further development of  the  patents  and
applications and related products. BioChem Solutions Inc. expects
to  schedule the third stage Clinical trials for treatment HIV  /
AIDS.


                             11



Item 2.  Management Discussion and Analysis and Plan of Operation
-----------------------------------------------------------------

All  statements  contained herein that are not historical  facts,
including   but   not  limited  to,  statements   regarding   the
anticipated  future  capital requirements and future  development
plans  are  based on current expectations. These  statements  are
forward  looking  in  nature and involve a number  of  risks  and
uncertainties.  Actual results may differ materially.  Among  the
factors that could cause actual results to differ materially  are
the  following:  amount  of  revenues  earned  by  the  Company's
operations; the availability of sufficient capital to finance the
Company's  business plan on terms satisfactory  to  the  Company;
general  business and economic conditions; and other risk factors
described  in the Company's reports filed from time to time  with
the  Commission. The Company wishes to caution readers  not    to
place    undue    reliance   on   any   such    forward   looking
statements,  which statements are made pursuant  to  the  Private
Securities Litigation Reform Act of 1995 and, as such, speak only
as of the date made.

Results of Operations
---------------------

Three  Months  Ended March 31, 2006,  versus Three  Months  Ended
March 31, 2005.

We  had no revenues for the three months ended March 31, 2006 and
2005.  There  is no assurance that we will any have  revenues  in
2006.   As  we had no sales in this quarter, we had  no  cost  of
sales for the quarters.

Operating expenses for the three months ended March 31, 2006 were
$  122,428 compared to $ 191,199 for the three months ended March
31, 2005.  Other income for the three months ended March 31, 2006
was  $0  as  compared to other income of $1,390 for three  months
ended  March 31, 2005.  Interest expense was $ 10,500  for  three
months  ended  March 31, 2006 versus $454 for  the  three  months
ended March 31, 2005.

The  Company's net loss for the three months ended March 31, 2006
was  $  132,928 as compared to a loss of $ 190,263 for the  three
months ended March 31, 2005.

Liquidity and Capital Resources
-------------------------------

On  March 31, 2006, the Company had a working capital deficit  of
approximately $ 1,775,000. Since its inception, the  Company  has
continued  to  sustain  losses. The  Company's  operations  since
inception  have been funded by the sale of common  and  preferred
stock, and proceeds from both secured and unsecured loans.  These
funds have been used for working capital and capital expenditures
and  other  corporate purchases.  The Company has had  losses  of
approximately $ 6,550,000 since inception. The Company is seeking
financing  through equity financing.  There can be  no  assurance
that  the  Company  will  be  able to  obtain  funding  at  terms
acceptable  to  the  Company.  These factors  indicate  that  the
Company may not be able to continue as a going concern.

Recent Accounting Pronouncements
--------------------------------

In  December  2004, the FASB issued SFAS No. 123 (revised  2004),
Share-Based  Payment ("FAS 123(R)"), a revision of SFAS  No.  123
("FAS 123").  For small business issuers, this Statement must  be
implemented at the beginning of the fiscal year that begins after
December 15, 2005. This Statement establishes standards  for  the
accounting  for  transactions in which an  entity  exchanges  its
equity   instruments   for  goods  or  services   and   addresses
transactions  in which an entity incurs liabilities  in  exchange


                             12



for  goods  or services that are based on the fair value  of  the
entity's  equity  instruments or  that  may  be  settled  by  the
issuance  of those equity instruments.  FAS 123 focuses primarily
on  accounting  for  transactions  in  which  an  entity  obtains
employee  services  in  share-based  payment  transactions.   The
original  pronouncement, issued in October 1995, defined  a  fair
value  based  method of accounting for share-based payments,  but
permitted  companies to disclose such payments  either  employing
the  fair  value  based  method of accounting  or  by  using  the
intrinsic  value method as defined by APB No. 25, Accounting  for
Stock  Issued  to Employees.  For companies reporting  under  the
intrinsic  value  method, FAS 123 required a pro  forma  footnote
disclosure  of  the  impact of the fair value  based  method  for
financial reporting purposes.  The 2004 revision to FAS 123,  FAS
123(R), eliminates the intrinsic value method as provided by  APB
No.   25.   Depending  upon  the  extent  to  which  the  Company
implements  share-based  compensation  plans,  adoption  of  this
statement  could  have a material impact on the Company's  future
consolidated financial statements.

Off-Balance Sheet Arrangements
------------------------------

The  Company does not maintain off-balance sheet arrangements nor
does  it  participate in non-exchange traded contracts  requiring
fair value accounting treatment.


                             13



Item 3.  Controls and Procedures
--------------------------------

In  accordance  with Exchange Act Rules 13a-15  and  15d-15,  the
Company's   management  carried  out  an  evaluation   with   the
participation of the Company's Chief Executive Officer and  Chief
Financial  Officer, its principal executive officer and principal
financial  officer,  respectively, of the  effectiveness  of  the
Company's disclosure controls and procedures as of the end of the
period  covered  by this report. Based upon that evaluation,  the
Chief Executive Officer and Chief Financial Officer concluded  as
of  the  end of the period covered by this Form 10-QSB  that  the
Company's  disclosure controls and procedures  are  effective  in
timely  alerting  them to material information  relating  to  the
Company  required to be included in periodic reports filed  under
the  Securities Exchange Act of 1934, as amended. There  were  no
changes   in  the  Company's  internal  controls  over  financial
reporting  identified in connection with the  evaluation  by  the
Chief Executive Officer and Chief Financial Officer that occurred
during the Company's fourth quarter that have materially affected
or  are  reasonably  likely to materially  affect  the  Company's
internal controls over financial reporting.


PART II - OTHER INFORMATION
---------------------------

Item 1.  Legal Proceedings
--------------------------

Due  to  our financial difficulties, we defaulted on a number  of
debt  and  lease obligations. We have several judgments  totaling
approximately  $378,000  that were entered  against  us.  We  are
currently   trying   to   resolve   these   obligations   through
settlements. However, there is no assurance that we will be  able
to settle on terms favorable to us and if we are unable to do so,
this  will  have  a  material adverse affect on  our  ability  to
operate properly in the future.

On  May  3, 2004, we received a letter from Pedro Fenando  Arizpe
Carreon,  a  shareholder of Grupo Industrial NKS,  S.A.  DE  C.V.
("NKS"),  addressed  to Montague Securities International,  Ltd.,
the escrow agent for the transaction by which we acquired 75%  of
the  outstanding  shares of capital stock  of  NKS.  Mr.  Carreon
alleged  that  we  had breached the Purchase Agreement.  We  have
denied any breach of the purchase agreement and have advised  Mr.
Carreon  in  writing  of this fact. On August  8,  2005,  Biochem
Solutions  filed  a civil complaint, in Broward County,  Florida,
against  Mr. Carreon and Grupo Industrial NKS alleging breach  of
contract  and  tortuous interference with a business relationship
and   requested  the  court  to  order  temporary  and  permanent
injunctive relief, declaratory judgment and monetary damages  for
the alleged interferences.


                             14




Item 2.  Change in Securities
-----------------------------

On  September 10, 2004, the holders of a majority of the Company'
outstanding voting shares executed a written consent amending the
Company's Articles of incorporation to increase the total  number
of   authorized  shares  of  the  Company's  Common  Stock   from
500,000,000 to 1,000,000,000.

As  of  March  15,  2005,  the Company  completed  a  transaction
resulting in the acquisition of 75% of all issued and outstanding
shares  of  Grupo  Industrial N.K.S.,  S.A.,  de  CV  ("NKS")  in
exchange  for  250,000,000  of  the Company's  common  restricted
shares. NKS, a Mexican corporation, is the owner of a steel  mill
foundry and other assets in Lazaro Cardenas, Mexico.

On  September  29,  2005  the Company's Board  approved  a  1:500
forward  split  after completing a 500:1 reverse stock  split  on
September   9,   2005  as  approved  by  the  majority   of   the
shareholders.


Item 3.  Defaults Upon Senior Securities
----------------------------------------

         Not applicable

Item 4.  Submission of Matters to a Vote of Security Holders
------------------------------------------------------------

         Not applicable

Item 5.   Subsequent Events
---------------------------

In  the United States District Court in the Southern District  of
California in San Diego, California, denied the Company's  motion
for  a  preliminary injunction in NorMexSteel, Inc.,  et  al.  v.
Charles B. Flynn, et al., Case Number 06-CV-0814, filed on  April
2,  2006.   In  the order dated June 6, 2006, the District  Court
reversed its tentative ruling.  The District Court's Findings  of
Fact  and  Conclusions  of  law Denying  Plaintiffs'  Motion  for
Preliminary  Injunction (the "Order") stated that:  "Although  in
its  tentative ruling the Court stated that it would  order  that
Defendants Baiaverde and Taurus place the allegedly stolen shares
in the registry of the Court pending resolution of the matter, it
has  reconsidered.   Upon further review, the  Court  finds  that
NorMex does not own the stock at issue here."  In the Order,  the
District Court denied the Plaintiffs' requested relief.

On June 16, 2006, the Company announced that by Consent to Act in
Lieu  of  a  meeting  of the shareholders, the  majority  of  the
shareholders  of  record voted and approved to unwind  the  share
exchange  with  Grupo Industrial NKS SA de CV.   The  250,000,000
shares issued to NKS shareholders will be voluntarily returned in
exchange  for  the 75% of the NKS shares held by NorMexSteel  and
the 250,000,000 NorMexSteel shares will be cancelled and returned
to  treasury. In conjunction with this the shareholders  approved
to  remove and replace the existing board of directors;  to  file
amendments  to the articles of Incorporation of the company  that
would  effect  a  name  change to BioChem Solutions  Inc.  and  a
reverse  stock  split  of the Company's common  stock  of  1  for
10,000.  Under  the guideline of the regulatory and  company  act
requirements the majority of shareholders agreed to the need  and
ratio of the reverse stock split and the majority agreed that the
restructuring  is  in the best interest of the company.  The  net
effect  of  the  reverse stock split will  reduce  the  Company's


                             15



outstanding  shares of common stock post split to  29,066  shares
(no  fractional  shares  will be issued).   The  stock  split  is
effective  as of June 30, 2006.  Shareholders of record  will  be
notified  by the Company's transfer agent and may exchange  their
old  shares  of common stock for new shares of common stock  post
reverse.

On  June 16, 2006, the Company entered into a contract to acquire
an Exclusive Rights and a Master License providing all the rights
in  a patented BioChemical, Trioxolane, and other patents held by
the  CKD  Foundation, the CKD Foundation will  appoint  five  new
directors to the board of directors.

BioChem  Solutions Inc. under the Master License from the  patent
holder,  the  CKD  Foundation, will provide  funding  on  a  best
efforts  basis  for the further development of  the  patents  and
applications and related products. BioChem Solutions Inc. expects
to  schedule the third stage Clinical trials for treatment HIV  /
AIDS.


                             16




Item 6.    Exhibits and Reports on Form 8-K
-------------------------------------------

     (a)  Exhibits and Index of Exhibits

     31.  Rule 13a-14(a)/15d-14(a) Certifications pursuant to
          Section 302 of the Sarbanes-Oxley Act of 2002.

     32.  Section 1350 Certification pursuant to Section 906 of the
          Sarbanes-Oxley Act of 2002.

     (b)  Reports on Form 8-K.
          On September 16, 2004, the Company filed a current
          report on Form 8-K in connection with the following:

          (i) as of September 10, 2004, the Company has finalized
          the Letter of Intent to originally acquire 100% of all
          classes of shares issued and outstanding of Grupo
          Industrial N.K.S., S.A., de CV, a Mexican corporation;

          (ii) on September 10, 2004, the holders of a majority
          of the Company' outstanding voting shares executed a
          written consent, amending the Company's Articles of
          incorporation to increase the total number of
          authorized shares of the Company's Common Stock from
          500,000,000 to 1,000,000,000, and

          (iii) on March 15, 2005, the Company completed the
          purchase of 75% of all outstanding shares on NKS.




                           SIGNATURES


Biochem Solutions Inc.

By /s/  James Herman
------------------------
James Herman, President

Date: November 16, 2006



                             17